- PUREVAX Recombinant FeLV is the first and only recombinant canarypox-vectored nonadjuvanted feline leukemia virus (FeLV) vaccine.
- PUREVAX FeLV provides efficacy equivalent to killed, adjuvanted FeLV vaccines.1
PUREVAX® Recombinant FeLV
PUREVAX® Recombinant FeLV contains a nonadjuvanted lyophilized suspension of a recombinant vectored feline leukemia vaccine plus sterile water diluent. A canarypox vector has been modified using recombinant technology to produce expression of desired antigens capable of stimulating a protective immune response to feline leukemia. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible cats.
This product has been shown to be effective for the vaccination of healthy cats, 8 weeks of age or older, against feline leukemia virus. The duration of immunity has not been determined. For more information regarding efficacy and safety data, see productdata.aphis.usda.gov.
Aseptically rehydrate the lyophilized vaccine with 0.5 mL of the accompanying sterile water diluent and agitate. Administer 1 dose subcutaneously. For primary vaccination, cats should receive 2 doses, 3 weeks apart. Diagnostic testing for FeLV prior to vaccination is recommended.
Precautions: Use entire contents immediately following rehydration. Contains gentamicin as a preservative. This product has not been tested in pregnant cats. In rare instances, administration of vaccines may cause transient pain associated with injection, lethargy, fever, and inflammatory or hypersensitivity types of reactions. Treatment may include antihistamines, anti-inflammatories, and/or epinephrine. In case of human exposure, contact a physician. Inactivate unused contents before disposal.
Store at 2-8ºC (35-46ºF). Do not use chemicals to sterilize syringes and needles. Do not mix with other products, except as specified on the label.
For use in animals only. Restricted to use by or under the direction of a veterinarian.
RECOMBITEK® Canine Vaccines
RECOMBITEK® vaccines are highly purified, making them a safe and effective option to help protect your canine patients from dangerous diseases.
IMRAB® Rabies Vaccines
Veterinarians worldwide trust US market-leading IMRAB® vaccines for proven multi-species rabies protection.4
PUREVAX® Feline Vaccines
Adjuvants can present potential risks to feline patients.2,5,6 PUREVAX® feline vaccines have been designed to elicit a protective immune response without the addition of adjuvants.
- Grosenbaugh DA, Frances-Duvert V, Abedi S, Feilmeier B, Ru H, Poulet H. Efficacy of a nonadjuvanted recombinant FeLV vaccine and two inactivated FeLV vaccines when subject to consistent virulent FeLV challenge conditions. Biologicals. 2017;49:76-80.
- Greene CE, Schultz RD. Immunoprophylaxis. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St Louis, MO: Elsevier Saunders; 2012:1166-1169.
- Taylor J, Meignier B, Tartglia J, et al. Biological and immunogenic properties of canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine. 1995; 13;6;539-549.
- Data on file at Boehringer Ingelheim.
- McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463-472.
- Day MJ, Schoon H-A, Magnol J-P, et al. A kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines. Vaccine. 2007; 25:4073-4084.
RECOMBITEK® and IMRAB® are registered trademarks and BI-CONNECT™ is a trademark of Boehringer Ingelheim Animal Health USA Inc. PUREVAX® is a registered trademark of Boehringer Ingelheim Animal Health France, used under license. ©2023 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved.